Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

1,630 public trials 214 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Active, Not Recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700

Conditions
B-cell Malignancies, Bone Marrow Diseases, Hematologic Diseases, +10 more
Locations
  • Uab Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of Alabama At Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Rochester Phoenix, Arizona, United States
  • University of Arizona Cancer Center-Out Pt. Tucson, Arizona, United States
View all 105 locations
View Trial Details
Active, Not Recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

NCT03213704

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 124 locations
View Trial Details
Active, Not Recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994

Conditions
Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 107 locations
View Trial Details
Active, Not Recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04320888

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +85 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 174 locations
View Trial Details
Active, Not Recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +74 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 116 locations
View Trial Details
Active, Not Recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details

Related conditions